A new study shows that one dose of a vaccine that can prevent the virus that leads to most cases of cervical cancer may be as effective as the usual two or three doses.
could have a significant impact on cutting the rate of cervical cancer worldwide, because a single dose would simplify the vaccination process and cost less. Cervical cancer is the fourth most common type of cancer among women, killing an estimated 342,000 worldwide in 2020.
The vaccine prevents transmission of cancer-causing strains of the sexually transmitted disease called human papillomavirus, or HPV. The first HPV vaccine was approved in the U.S. in 2006, and the CDC currently recommends two or three doses, depending on a person’s age. The new findings were presented at the end of April during the 35th International Papillomavirus Conference in Washington, DC. The study included 2,275 people in Kenya who ranged in age from 15 to 20 years old. They were randomly assigned to receive one of three treatments: a single-dose vaccine that targets two HPV strains, a single-dose HPV vaccine that targets nine strains, or a control vaccine. Participants were regularly tested for 3 years.
“Following the WHO recommendation in support of a one-dose regimen for HPV vaccine could help make the vaccine more accessible to women and girls around the world by lowering costs, alleviating pressure on supply, and making the vaccine easier to deliver,” Peter Dull, MD, deputy director for clinical vaccine development at the Bill & Melinda Gates Foundation, which funded the research, said in a statement..
Massachusetts General Hospital: “Research Spotlight: Single Dose of HPV is Highly Efficacious in Protecting Young Women.”The New York Times© 2023 WebMD, LLC. All rights reserved.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA approves world's first RSV vaccine, a shot for adults ages 60 and upBREAKING: FDA approves the world's first respiratory syncytial virus, or RSV, vaccine made by pharmaceutical giant GSK.
Consulte Mais informação »
FDA approves world’s first RSV vaccine, a shot for older adultsIn a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness by 83% and of severe illness by 94%.
Consulte Mais informação »
MIT’s Vaccine Printer: The Game-Changer in Vaccine DistributionThe printer generates vaccine-filled microneedle patches that can be stored long-term at room temperature and applied to the skin. Getting vaccines to people who need them isn’t always easy. Many vaccines require cold storage, making it difficult to ship them to remote areas that don’t have the n
Consulte Mais informação »
Silent Epidemic: Oral Sex Is Now the Leading Risk Factor for Throat CancerThe rapid rise in oropharyngeal cancer in the West over the past two decades is largely attributed to the sexually transmitted human papillomavirus (HPV). Despite the potential protective effect of HPV vaccinations, challenges such as vaccine hesitancy, low coverage in certain regions, and behaviora
Consulte Mais informação »
UK listing shakeup requires double dose of hopeBritain’s financial watchdog wants to spur domestic IPO markets by weakening shareholder protections. Yet making London appealing to fast-growing foreign firms requires wider reforms that may not occur. And lower standards are only a good idea if investors punish bad governance.
Consulte Mais informação »
Breakingviews - UK listing shakeup requires double dose of hopeThe UK is trying to do something about its dwindling listings. Britain’s financial watchdog wants to spur domestic IPO markets by weakening shareholder protections. Yet making London appealing to fast-growing foreign firms requires wider reforms, and lower standards are only a good idea if investors punish bad governance.
Consulte Mais informação »